PCM Trials Acquires EmVenio Research
Effective immediately, the acquisition strengthens both organizations’ abilities to recruit and retain diverse populations for clinical trials.
PCM Trials has announced the acquisition of EmVenio Research, according to a press release.1 Effective immediately, the acquisition strengthens PCM Trials' and EmVenio's abilities to recruit and retain diverse populations for clinical research studies, as required for regulatory approval. Following the acquisition, PCM Trials now has access to a site network that is focused on serving underrepresented patient populations in previously hard-to-reach communities and can work flexibly with sponsors to achieve their study goals.
"The acquisition of EmVenio is an important part of our company's overall strategy to further remove barriers for patients of all backgrounds and ethnicities to participate in clinical research, creating the most patient-centric clinical trial model," said Greg Austin, president of PCM Trials in the press release. "Our pioneering approach to using Certified Mobile Research Nurses who visit patients in their homes has already been shown to improve both patient retention and diversity in clinical trials and drive faster study completion. Now, with the addition of EmVenio's mobile research site network, we have the unmatched ability to provide additional convenience for prospective participants, empowering community-based clinical trial access."
EmVenio has activated 63 mobile sites across over 22 states in the United States plus 10 locations in the United Kingdom. Additionally, the community-based clinical trial site provider has contracted 25 studies across numerous therapeutic areas.
This most recent acquisition of EmVenio marks the second completed by PCM Trials within the past month. On January 10, the company announced the acquisition of Netherlands-based Clinical Trial Service (CTS), which solidified PCM Trials' ability and reach to successfully conduct global clinical trials.2
"We are thrilled to announce the culmination of EmVenio's and PCM Trials' efforts in creating the most comprehensive global capability for patient visits, spanning from traditional site settings to the comfort of one's home, and everywhere in between through mobile sites," said Thad Wolfram, president of EmVenio in the press release. "Our combined services prioritize minimizing burdens for research participation while enhancing the overall participant experience."
References
1. PCM Trials Acquires EmVenio Research to Create the Most Patient-Centric Model for Hybrid and Decentralized Clinical Trials. News release. February 23, 2024. Accessed March 13, 2024. https://www.prnewswire.com/news-releases/pcm-trials-acquires-emvenio-research-to-create-the-most-patient-centric-model-for-hybrid-and-decentralized-clinical-trials-302070059.html
2. PCM Trials Acquires Netherlands-Based Clinical Trial Service B.V., Becoming the Most Experienced Independent Provider of Mobile Visit Services with The Largest Geographic Coverage Area in Support of Decentralized Clinical Trials. News release. January 10, 2024. Accessed March 13, 2024. https://www.prnewswire.com/news-releases/pcm-trials-acquires-netherlands-based-clinical-trial-service-bv-becoming-the-most-experienced-independent-provider-of-mobile-visit-services-with-the-largest-geographic-coverage-area-in-support-of-decentralized-clinical-trials-302030478.html
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
